EA201890671A1 - Препараты полипептида фактора viii - Google Patents
Препараты полипептида фактора viiiInfo
- Publication number
- EA201890671A1 EA201890671A1 EA201890671A EA201890671A EA201890671A1 EA 201890671 A1 EA201890671 A1 EA 201890671A1 EA 201890671 A EA201890671 A EA 201890671A EA 201890671 A EA201890671 A EA 201890671A EA 201890671 A1 EA201890671 A1 EA 201890671A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fviii
- factor viii
- polypeptide
- drugs
- polypeptide factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
В настоящем изобретении предложен препарат полипептида фактора VIII, например FVIII-Fc, и способы его применения. Полипептид FVIII может представлять собой рекомбинантный белок FVIII, белок FVIII короткого действия или белок FVIII длительного действия. Фармацевтический препарат, содержащий полипептид FVIII, можно применять для индивидуальной профилактики, недельной профилактики, эпизодического (по необходимости) лечения или периоперационного ведения гемофилии.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361800293P | 2013-03-15 | 2013-03-15 | |
US201361817085P | 2013-04-29 | 2013-04-29 | |
US201361829884P | 2013-05-31 | 2013-05-31 | |
US201361839477P | 2013-06-26 | 2013-06-26 | |
US201361863860P | 2013-08-08 | 2013-08-08 | |
US201361876927P | 2013-09-12 | 2013-09-12 | |
US201361879955P | 2013-09-19 | 2013-09-19 | |
US201361897742P | 2013-10-30 | 2013-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890671A1 true EA201890671A1 (ru) | 2019-01-31 |
Family
ID=50771579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591439A EA030357B1 (ru) | 2013-03-15 | 2014-03-14 | Препараты полипептида фактора viii |
EA201890671A EA201890671A1 (ru) | 2013-03-15 | 2014-03-14 | Препараты полипептида фактора viii |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591439A EA030357B1 (ru) | 2013-03-15 | 2014-03-14 | Препараты полипептида фактора viii |
Country Status (21)
Country | Link |
---|---|
US (3) | US9623088B2 (ru) |
EP (3) | EP3666283B1 (ru) |
JP (5) | JP6330026B2 (ru) |
AU (3) | AU2014228506A1 (ru) |
CA (1) | CA2899737A1 (ru) |
CL (1) | CL2015002720A1 (ru) |
DK (1) | DK2968477T3 (ru) |
EA (2) | EA030357B1 (ru) |
ES (2) | ES2926798T3 (ru) |
HK (1) | HK1220617A1 (ru) |
HU (1) | HUE047933T2 (ru) |
LT (1) | LT2968477T (ru) |
PH (2) | PH12015501801A1 (ru) |
PL (2) | PL2968477T3 (ru) |
PT (2) | PT3666283T (ru) |
RS (1) | RS60003B1 (ru) |
SG (2) | SG11201505924TA (ru) |
SI (1) | SI2968477T1 (ru) |
TW (2) | TWI690325B (ru) |
UY (1) | UY35462A (ru) |
WO (1) | WO2014144795A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ703153A (en) * | 2009-12-06 | 2015-02-27 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
HUE047933T2 (hu) * | 2013-03-15 | 2020-05-28 | Bioverativ Therapeutics Inc | Faktor VIII polipeptid készítmények |
TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors |
CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
JP7039308B2 (ja) * | 2017-02-08 | 2022-03-22 | 三洋化成工業株式会社 | 細胞培養用担体 |
CA3072334A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
AU2018366110A1 (en) * | 2017-11-07 | 2020-06-04 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
CN113227385A (zh) | 2018-08-09 | 2021-08-06 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
EP3870206A4 (en) * | 2018-10-23 | 2023-04-26 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION |
JPWO2020175594A1 (ru) * | 2019-02-28 | 2020-09-03 | ||
MX2021012540A (es) | 2019-04-17 | 2022-01-18 | Codiak Biosciences Inc | Composiciones de exosomas y virus adenoasociados (aav). |
TW202115127A (zh) | 2019-06-19 | 2021-04-16 | 美商百歐維拉提夫治療公司 | 治療血友病及低骨質密度之方法及組成物 |
KR20230159285A (ko) * | 2022-05-10 | 2023-11-21 | 주식회사 녹십자 | 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물 |
WO2023219378A1 (ko) * | 2022-05-10 | 2023-11-16 | 주식회사 녹십자 | 혈장 단백질에 대한 신규한 액상 제형물 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
NZ256921A (en) * | 1992-10-02 | 1996-05-28 | Pharmacia Ab | Formulations of coagulation factor viii and a non-ionic surfactant and their preparation |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
EP1820516B1 (en) * | 1999-02-22 | 2013-07-24 | University of Connecticut | Novel albumin-free factor VIII formulations |
CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004239244C1 (en) | 2003-05-06 | 2015-04-23 | Bioverativ Therapeutics Inc. | Clotting factor-Fc chimeric proteins to treat hemophilia |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
WO2005058283A2 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor vii polypeptides |
SI3130601T1 (sl) | 2004-11-12 | 2020-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
US8239182B2 (en) | 2007-12-04 | 2012-08-07 | Spansion Llc | Data transmission system-on-chip memory model based validation |
EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
JP5770161B2 (ja) * | 2009-04-06 | 2015-08-26 | ノヴォ ノルディスク アー/エス | 血小板への第viii因子タンパク質の標的送達 |
NZ703153A (en) | 2009-12-06 | 2015-02-27 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
LT3513804T (lt) | 2011-07-08 | 2022-05-25 | Bioverativ Therapeutics Inc. | Viii faktorius chimeriniai ir hibridiniai polipetidai bei jų panaudojimo būdai |
EP2768853A1 (en) | 2011-10-18 | 2014-08-27 | CSL Limited | Method for improving the stability of purified factor viii after reconstitution |
US20160000884A1 (en) | 2012-08-13 | 2016-01-07 | Novo Nordisk A/S | Liquid Factor VIII Formulations |
EP3943102A1 (en) * | 2012-10-30 | 2022-01-26 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
HUE047933T2 (hu) * | 2013-03-15 | 2020-05-28 | Bioverativ Therapeutics Inc | Faktor VIII polipeptid készítmények |
-
2014
- 2014-03-14 HU HUE14725816A patent/HUE047933T2/hu unknown
- 2014-03-14 RS RS20200243A patent/RS60003B1/sr unknown
- 2014-03-14 PT PT192129005T patent/PT3666283T/pt unknown
- 2014-03-14 UY UY0001035462A patent/UY35462A/es not_active Application Discontinuation
- 2014-03-14 PL PL14725816T patent/PL2968477T3/pl unknown
- 2014-03-14 AU AU2014228506A patent/AU2014228506A1/en not_active Abandoned
- 2014-03-14 EP EP19212900.5A patent/EP3666283B1/en active Active
- 2014-03-14 EP EP14725816.4A patent/EP2968477B1/en active Active
- 2014-03-14 TW TW107113370A patent/TWI690325B/zh active
- 2014-03-14 CA CA2899737A patent/CA2899737A1/en active Pending
- 2014-03-14 US US14/213,180 patent/US9623088B2/en active Active
- 2014-03-14 ES ES19212900T patent/ES2926798T3/es active Active
- 2014-03-14 SG SG11201505924TA patent/SG11201505924TA/en unknown
- 2014-03-14 SG SG10201805207QA patent/SG10201805207QA/en unknown
- 2014-03-14 DK DK14725816.4T patent/DK2968477T3/da active
- 2014-03-14 WO PCT/US2014/029354 patent/WO2014144795A1/en active Application Filing
- 2014-03-14 PL PL19212900.5T patent/PL3666283T3/pl unknown
- 2014-03-14 JP JP2016503069A patent/JP6330026B2/ja active Active
- 2014-03-14 LT LTEP14725816.4T patent/LT2968477T/lt unknown
- 2014-03-14 EA EA201591439A patent/EA030357B1/ru unknown
- 2014-03-14 ES ES14725816T patent/ES2776195T3/es active Active
- 2014-03-14 PT PT147258164T patent/PT2968477T/pt unknown
- 2014-03-14 SI SI201431514T patent/SI2968477T1/sl unknown
- 2014-03-14 EA EA201890671A patent/EA201890671A1/ru unknown
- 2014-03-14 EP EP22176875.7A patent/EP4122487A1/en active Pending
- 2014-03-14 TW TW103109616A patent/TWI629993B/zh active
-
2015
- 2015-08-14 PH PH12015501801A patent/PH12015501801A1/en unknown
- 2015-09-15 CL CL2015002720A patent/CL2015002720A1/es unknown
-
2016
- 2016-07-20 HK HK16108672.0A patent/HK1220617A1/zh unknown
-
2017
- 2017-03-09 US US15/455,043 patent/US10786554B2/en active Active
-
2018
- 2018-04-23 JP JP2018082321A patent/JP2018123161A/ja not_active Ceased
-
2019
- 2019-04-16 AU AU2019202656A patent/AU2019202656B2/en active Active
- 2019-10-30 PH PH12019502452A patent/PH12019502452A1/en unknown
-
2020
- 2020-08-14 US US16/993,979 patent/US20210069300A1/en active Pending
- 2020-08-19 JP JP2020138637A patent/JP6934994B2/ja active Active
-
2021
- 2021-08-24 JP JP2021136162A patent/JP7240457B2/ja active Active
- 2021-11-29 AU AU2021277601A patent/AU2021277601A1/en active Pending
-
2023
- 2023-03-03 JP JP2023032892A patent/JP2023060146A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591439A1 (ru) | Препараты полипептида фактора viii | |
EA202090919A1 (ru) | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a | |
MX2019003716A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
MX2021005907A (es) | Formulaciones de proteinas liquidas que contienen liquidos ionicos. | |
CY1122796T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων | |
EA202091342A2 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201991029A1 (ru) | Ингибиторы magl | |
UY35306A (es) | Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina. | |
EA201690159A1 (ru) | Способы и композиции для лечения рака | |
EA201590162A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
TN2014000498A1 (en) | Pharmaceutical formulation | |
EA201700019A1 (ru) | Высокочистый оритаванцин и способ его получения | |
MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
EA201501028A1 (ru) | Конструкции митохондриальных белков и их применение | |
EA201591421A1 (ru) | Препараты полипептида фактора ix | |
UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
PH12016500738A1 (en) | Formulation for gonadotropins | |
MX2015016492A (es) | Peptidos de y conotoxina, composicion farmaceutica y usos de los mismos. | |
EA201690826A1 (ru) | Рекомбинантные гликопротеиды и их применения | |
WO2018204617A8 (en) | STABLE FORMULATIONS OF MYOSTATIN-BOUND FIBRONECTIN SCAFFOLDING DOMAIN PROTEIN | |
AR122764A2 (es) | Formulación de un polipéptido del factor viii, kit farmacéutico, método |